Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib in MDS/MPNs and CNL
NCT05177211Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fedratinib in myelodysplastic/myeloproliferative neoplasm (MDS/MPN), chronic neutrophilic leukemia (CNL) and Atypical chronic myeloid leukemia (aCML), sponsored by Moffitt Cancer Center. Primary endpoint: Objective Clinical Response Rate at 24 weeks. Started Mar 2022; status: completed.
02
Drugs
fedratinib
03
Conditions
myelodysplastic/myeloproliferative neoplasm (MDS/MPN)chronic neutrophilic leukemia (CNL)Atypical chronic myeloid leukemia (aCML)
Beyond the preview
Go deeper on NCT05177211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05177211.